vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and e.l.f. Beauty, Inc. (ELF). Click either name above to swap in a different company.

e.l.f. Beauty, Inc. is the larger business by last-quarter revenue ($489.5M vs $406.6M, roughly 1.2× BIOCRYST PHARMACEUTICALS INC). BIOCRYST PHARMACEUTICALS INC runs the higher net margin — 60.5% vs 8.0%, a 52.4% gap on every dollar of revenue. On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (209.1% vs 37.8%). BIOCRYST PHARMACEUTICALS INC produced more free cash flow last quarter ($291.2M vs $52.8M).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

e.l.f. Beauty, Inc. is an American cosmetics brand based in Oakland, California. It was founded by Joseph Shamah and Scott Vincent Borba in 2004. The company sells items include bath and skin-care products, mineral-based makeup, professional tools, eyeliners, lipstick, glosses, blushes, bronzers, brushes and mascara. Its products are sold in 18 countries and in several stores including Target, Kmart, Dollar General and Walmart. Over half the company's sales come from its website, which is als...

BCRX vs ELF — Head-to-Head

Bigger by revenue
ELF
ELF
1.2× larger
ELF
$489.5M
$406.6M
BCRX
Growing faster (revenue YoY)
BCRX
BCRX
+171.3% gap
BCRX
209.1%
37.8%
ELF
Higher net margin
BCRX
BCRX
52.4% more per $
BCRX
60.5%
8.0%
ELF
More free cash flow
BCRX
BCRX
$238.4M more FCF
BCRX
$291.2M
$52.8M
ELF

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
BCRX
BCRX
ELF
ELF
Revenue
$406.6M
$489.5M
Net Profit
$245.8M
$39.4M
Gross Margin
97.7%
71.0%
Operating Margin
64.0%
13.8%
Net Margin
60.5%
8.0%
Revenue YoY
209.1%
37.8%
Net Profit YoY
1017.5%
128.1%
EPS (diluted)
$1.13
$0.65

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
ELF
ELF
Q4 25
$406.6M
$489.5M
Q3 25
$159.4M
$343.9M
Q2 25
$163.4M
$353.7M
Q1 25
$145.5M
Q4 24
$131.5M
Q3 24
$117.1M
Q2 24
$109.3M
Q1 24
$92.8M
Net Profit
BCRX
BCRX
ELF
ELF
Q4 25
$245.8M
$39.4M
Q3 25
$12.9M
$3.0M
Q2 25
$5.1M
$33.3M
Q1 25
$32.0K
Q4 24
$-26.8M
Q3 24
$-14.0M
Q2 24
$-12.7M
Q1 24
$-35.4M
Gross Margin
BCRX
BCRX
ELF
ELF
Q4 25
97.7%
71.0%
Q3 25
98.6%
69.4%
Q2 25
98.3%
69.1%
Q1 25
96.9%
Q4 24
95.4%
Q3 24
97.3%
Q2 24
98.4%
Q1 24
98.6%
Operating Margin
BCRX
BCRX
ELF
ELF
Q4 25
64.0%
13.8%
Q3 25
18.6%
2.2%
Q2 25
18.2%
13.8%
Q1 25
14.6%
Q4 24
-3.4%
Q3 24
6.6%
Q2 24
8.0%
Q1 24
-15.6%
Net Margin
BCRX
BCRX
ELF
ELF
Q4 25
60.5%
8.0%
Q3 25
8.1%
0.9%
Q2 25
3.1%
9.4%
Q1 25
0.0%
Q4 24
-20.4%
Q3 24
-12.0%
Q2 24
-11.6%
Q1 24
-38.1%
EPS (diluted)
BCRX
BCRX
ELF
ELF
Q4 25
$1.13
$0.65
Q3 25
$0.06
$0.05
Q2 25
$0.02
$0.58
Q1 25
$0.00
Q4 24
$-0.13
Q3 24
$-0.07
Q2 24
$-0.06
Q1 24
$-0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
ELF
ELF
Cash + ST InvestmentsLiquidity on hand
$274.7M
$196.8M
Total DebtLower is stronger
$816.7M
Stockholders' EquityBook value
$-119.2M
$1.2B
Total Assets
$514.2M
$2.3B
Debt / EquityLower = less leverage
0.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
ELF
ELF
Q4 25
$274.7M
$196.8M
Q3 25
$212.9M
$194.4M
Q2 25
$260.0M
$170.0M
Q1 25
$295.1M
Q4 24
$320.9M
Q3 24
$96.8M
Q2 24
$78.4M
Q1 24
$84.3M
Total Debt
BCRX
BCRX
ELF
ELF
Q4 25
$816.7M
Q3 25
$831.6M
Q2 25
$256.7M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BCRX
BCRX
ELF
ELF
Q4 25
$-119.2M
$1.2B
Q3 25
$-387.9M
$1.1B
Q2 25
$-421.6M
$804.9M
Q1 25
$-451.9M
Q4 24
$-475.9M
Q3 24
$-468.6M
Q2 24
$-475.6M
Q1 24
$-476.2M
Total Assets
BCRX
BCRX
ELF
ELF
Q4 25
$514.2M
$2.3B
Q3 25
$446.4M
$2.3B
Q2 25
$457.2M
$1.3B
Q1 25
$480.0M
Q4 24
$490.4M
Q3 24
$491.3M
Q2 24
$472.4M
Q1 24
$467.9M
Debt / Equity
BCRX
BCRX
ELF
ELF
Q4 25
0.70×
Q3 25
0.73×
Q2 25
0.32×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
ELF
ELF
Operating Cash FlowLast quarter
$292.0M
$59.4M
Free Cash FlowOCF − Capex
$291.2M
$52.8M
FCF MarginFCF / Revenue
71.6%
10.8%
Capex IntensityCapex / Revenue
0.2%
1.4%
Cash ConversionOCF / Net Profit
1.19×
1.51×
TTM Free Cash FlowTrailing 4 quarters
$344.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
ELF
ELF
Q4 25
$292.0M
$59.4M
Q3 25
$41.6M
$23.4M
Q2 25
$41.3M
$27.2M
Q1 25
$-27.5M
Q4 24
$-5.2M
Q3 24
$8.2M
Q2 24
$-1.4M
Q1 24
$-53.7M
Free Cash Flow
BCRX
BCRX
ELF
ELF
Q4 25
$291.2M
$52.8M
Q3 25
$40.3M
$16.6M
Q2 25
$41.1M
$20.1M
Q1 25
$-27.7M
Q4 24
$-5.9M
Q3 24
$8.2M
Q2 24
$-1.5M
Q1 24
$-53.9M
FCF Margin
BCRX
BCRX
ELF
ELF
Q4 25
71.6%
10.8%
Q3 25
25.3%
4.8%
Q2 25
25.2%
5.7%
Q1 25
-19.0%
Q4 24
-4.5%
Q3 24
7.0%
Q2 24
-1.4%
Q1 24
-58.1%
Capex Intensity
BCRX
BCRX
ELF
ELF
Q4 25
0.2%
1.4%
Q3 25
0.8%
2.0%
Q2 25
0.1%
2.0%
Q1 25
0.1%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Q1 24
0.3%
Cash Conversion
BCRX
BCRX
ELF
ELF
Q4 25
1.19×
1.51×
Q3 25
3.23×
7.82×
Q2 25
8.12×
0.82×
Q1 25
-859.91×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons